Poison and Drug info :  1-800-222-1222
Tucson Campus: 520-626-1427
Phoenix Campus: 602-827-2426

Jianqin Lu, BPharm, PhD

Assistant Professor, Pharmaceutics and Pharmacokinetics
Director, Pharmaceutics and Pharmacokinetics Track
Assistant Professor, BIO5 Institute
Member, NCI designated UA Comprehensive Cancer Center
Member, Southwest Environmental Health Sciences Center

Jianqin Lu, BPharm, PhD, is an Assistant Professor of Pharmaceutical Sciences in Pharmaceutics and Pharmacokinetics at The University of Arizona R. Ken Coit College of Pharmacy. The Lu research laboratory strives to develop innovative, safe, and efficacious therapeutics at the interface of drug delivery, synthetic chemistry, pharmaceutics, nanotechnology, and tumor immunology to address the pressing unmet needs in current cancer and other diseases therapy and prevention, particularly in the emerging field of combination immunochemotherapy. Dr. Lu was the recipient of the Norman R. and Priscilla A. Farnsworth Award at the University of Pittsburgh, the USHHS Ruth L. Kirschstein Institutional National Research Service Award in Tumor Immunology, and the PhRMA Foundation Research Starter Grant in Drug Delivery, among others. Dr. Lu currently serves as the Director for Pharmaceutics and Pharmacokinetics Track at R. Ken Coit College of Pharmacy, the Secretary of Knowledge Management in Pharmaceutics Section of the American Association of Colleges of Pharmacy (AACP), and the Associate Editor for Frontiers in Medical Technology: Nano-Based Drug Delivery.

 

Education & Post Graduate Training: 

Postdoc, Nanomedicine/Tumor Immunology, University of California, Los Angeles, 2019
Postdoc, Nanomedicine, The University of Chicago, Chicago, 2015
PhD, Pharmaceutics, University of Pittsburgh, Pittsburgh, 2014
BS, Pharmacy, Hunan University of Chinese Medicine, Changsha, China, 2010

Areas of Research: 

Drug Delivery
Nanomedicine
Pharmaceutics and Pharmacokinetics
Nano-ImmunoEngineering
Cancer Immunotherapy
Chemotherapy
Biomaterials

Types of Research:

Laboratory-based Research
Basic and Applied Sciences
Industry
Translational Medicine

Select Publications

2021

Li W, Little N, Park J, Foster CAlexander, Chen J, Lu J. "Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges." Mol Pharm. 2021;18(8):2889-2905. PMID: 34260250
Wang Z, Little N, Chen J, et al. "Immunogenic camptothesome nanovesicles comprising sphingomyelin-derived camptothecin bilayers for safe and synergistic cancer immunochemotherapy." Nat Nanotechnol. 2021. PMID: 34385682

2020

Wang Z, Chen J, Little N, Lu J. "Self-assembling Prodrug Nanotherapeutics for Synergistic Tumor Targeted Drug Delivery." Acta Biomater. 2020. PMCID: PMC7245299  PMID: 32454086

2019

Wang X, Chang CHyun, Jiang J, et al. "The Crystallinity and Aspect Ratio of Cellulose Nanomaterials Determine Their Pro-Inflammatory and Immune Adjuvant Effects In Vitro and In Vivo." Small. 2019;15(42):e1901642. PMCID: PMC6800804  PMID: 31461215
Liu Q, Wang X, Liu X, et al. "Use of Polymeric Nanoparticle Platform Targeting the Liver To Induce Treg-Mediated Antigen-Specific Immune Tolerance in a Pulmonary Allergen Sensitization Model." ACS Nano. 2019;13(4):4778-4794. PMCID: PMC6506187  PMID: 30964276
Liu X, Jiang J, Chan R, et al. "Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer." ACS Nano. 2019;13(1):38-53. PMCID: PMC6554030  PMID: 30525443
Ji Y, Liu X, Huang M, et al. "Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo." Biomaterials. 2019;192:416-428. PMCID: PMC6934403  PMID: 30500723

2018

Wang X, Lee J-H, Li R, et al. "Toxicological Profiling of Highly Purified Single-Walled Carbon Nanotubes with Different Lengths in the Rodent Lung and Escherichia Coli." Small. 2018;14(23):e1703915. PMCID: PMC6239219  PMID: 29733549

2017

Liu X, Jiang J, Ji Y, Lu J, Chan R, Meng H. "Targeted drug delivery using iRGD peptide for solid cancer treatment." Mol Syst Des Eng. 2017;2(4):370-379. PMCID: PMC6258069  PMID: 30498580
Lu J, Liu X, Liao Y-P, et al. "Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression." Nat Commun. 2017;8(1):1811. PMCID: PMC5703845  PMID: 29180759